"Half of all breast cancers are hormone receptor-positive, HER2-negative, and axillary node-negative,” Dr. Sparano explained in the ASCO press release. “Our study shows that chemotherapy may be avoided in about 70 percent of these women when its use is guided by the [Oncotype Dx®] test, thus limiting chemotherapy to the 30 percent who we can predict will benefit from it.” https://www.bcrf.org/blog/bcrf....-supported-study-sho
Like
Comment
Share
